BNP Paribas Financial Markets Invests $507,000 in Nkarta, Inc. (NASDAQ:NKTX)

BNP Paribas Financial Markets purchased a new position in Nkarta, Inc. (NASDAQ:NKTX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 203,595 shares of the company's stock, valued at approximately $507,000. BNP Paribas Financial Markets owned approximately 0.29% of Nkarta as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently modified their holdings of the stock. Wellington Management Group LLP raised its holdings in shares of Nkarta by 4.1% in the 4th quarter. Wellington Management Group LLP now owns 225,224 shares of the company's stock valued at $561,000 after buying an additional 8,883 shares during the period. JPMorgan Chase & Co. raised its stake in Nkarta by 138.7% during the 4th quarter. JPMorgan Chase & Co. now owns 2,537,922 shares of the company's stock worth $6,319,000 after acquiring an additional 1,474,560 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Nkarta by 41.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,958 shares of the company's stock valued at $60,000 after purchasing an additional 7,030 shares during the last quarter. Sequoia Financial Advisors LLC acquired a new stake in shares of Nkarta in the fourth quarter valued at approximately $31,000. Finally, American Century Companies Inc. raised its holdings in shares of Nkarta by 8.8% in the fourth quarter. American Century Companies Inc. now owns 90,952 shares of the company's stock valued at $226,000 after buying an additional 7,378 shares during the last quarter. Institutional investors and hedge funds own 80.54% of the company's stock.

Nkarta Trading Up 2.8%

Nkarta stock traded up $0.05 on Thursday, reaching $1.81. 227,784 shares of the stock were exchanged, compared to its average volume of 1,062,223. The firm has a fifty day moving average price of $1.82 and a two-hundred day moving average price of $2.11. The stock has a market cap of $128.43 million, a PE ratio of -0.96 and a beta of 0.81. Nkarta, Inc. has a twelve month low of $1.31 and a twelve month high of $8.23.

Nkarta (NASDAQ:NKTX - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.01. Equities analysts anticipate that Nkarta, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on NKTX shares. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price objective on shares of Nkarta in a report on Thursday, March 27th. Needham & Company LLC decreased their target price on shares of Nkarta from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Thursday, May 15th. William Blair reaffirmed a "market perform" rating on shares of Nkarta in a research report on Thursday, May 15th. Finally, Stifel Nicolaus reduced their price target on shares of Nkarta from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, March 27th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $14.67.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.